Zymeworks Inc.
Ownership
Ownership Structure
Who owns Zymeworks Inc. (ZYME)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 93.1% of the shares are freely tradable; institutional investors hold 98.8%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 32.01 | 22,970,388 | +0.0 | 06/30/2026 |
| Rubric Capital Management LP | 9.76 | 7,000,000 | +0.0 | 06/30/2026 |
| BlackRock Inc | 5.92 | 4,251,030 | -6.7 | 06/30/2026 |
| Perceptive Advisors LLC | 5.83 | 4,182,953 | +19.2 | 06/30/2026 |
| Bvf Inc | 5.09 | 3,649,142 | -2.3 | 06/30/2026 |
| Assenagon Asset Management SA | 3.49 | 2,504,054 | +244.0 | 06/30/2026 |
| Morgan Stanley - Brokerage Accounts | 3.11 | 2,231,260 | -10.1 | 06/30/2026 |
| BNP Paribas Investment Partners SA | 2.48 | 1,781,116 | -6.7 | 06/30/2026 |
| Vanguard Capital Management, LLC | 2.17 | 1,558,998 | -8.6 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| HBM Healthcare Investments AG Ord | 3.52 | 2,522,736 | +0.0 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Schayowitz Adam | EVP, Head of R&D | 23,205 | 663,663 $ | Oct 9, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 9, 2026 | Schayowitz Adam | EVP, Head of R&D | Sell | 13,832 | 25.85 | 357,557 |
| Oct 9, 2026 | Schayowitz Adam | EVP, Head of R&D | Other | 37,037 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.